Olopatadine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Fixed typo
Tags: canned edit summary Mobile edit Mobile app edit
Added reference
Line 40: Line 40:
}}
}}


'''Olopatadine hydrochloride''' is an [[antihistamine]] (as well as [[anticholinergic]] and [[mast cell]] stabilizer), sold as a [[Prescription drug|prescription]] [[eye drop]] manufactured by [[Alcon]] in one of three strengths: 0.7% solution or '''Pazeo''' in the US, 0.2% solution or '''Pataday''' (also called '''Patanol S''' in some countries), and 0.1% or '''Patanol''' (also called '''Opatanol''' in some countries; Olopat in India). It is used to treat itching associated with allergic [[conjunctivitis]] (eye [[allergy|allergies]]). A steroid-free<ref>[https://www.patanase.com/about/steroid-free-nasal-spray.aspx How PATANASE® Nasal Spray Works]</ref> [[nasal spray]] formulation is sold as '''Patanase''', which was approved by the FDA on April 15, 2008.<ref>[http://www.drugs.com/newdrugs/alcon-s-patanase-nasal-approved-fda-nasal-allergy-symptoms-942.html Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms]</ref> It is also available as an oral tablet in Japan under the tradename '''Allelock''', manufactured by Kyowa Hakko Kogyo.<ref name=KYOWA08>{{cite web | author = Kyowa Hakko Kogyo Co., Ltd. | year = 2007 | url = http://www.e-search.ne.jp/~jpr/PDF/KYOWA08.PDF |format=PDF| title = ALLELOCK Tablets 2.5 & ALLELOCK Tablets 5 (English) | accessdate = 2008-08-10}}</ref>
'''Olopatadine hydrochloride''' is an [[antihistamine]] (as well as [[anticholinergic]] and [[mast cell]] stabilizer), sold as a [[Prescription drug|prescription]] [[eye drop]] manufactured by [[Alcon]] in one of three strengths: 0.7% solution or '''Pazeo''' in the US, 0.2% solution or '''Pataday''' (also called '''Patanol S''' in some countries), and 0.1% or '''Patanol''' (also called '''Opatanol''' in some countries; Olopat in India). It is used to treat itching associated with allergic [[conjunctivitis]] (eye [[allergy|allergies]]).<ref name="Castillo">{{cite journal |authors=Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A |title= Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis |journal=Cochrane Database Syst Rev|volume=6 |pages= CD009566 |date=2015 |pmid= 26028608 |doi= 10.1002/14651858.CD009566.pub2}}</ref> A steroid-free<ref>[https://www.patanase.com/about/steroid-free-nasal-spray.aspx How PATANASE® Nasal Spray Works]</ref> [[nasal spray]] formulation is sold as '''Patanase''', which was approved by the FDA on April 15, 2008.<ref>[http://www.drugs.com/newdrugs/alcon-s-patanase-nasal-approved-fda-nasal-allergy-symptoms-942.html Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms]</ref> It is also available as an oral tablet in Japan under the tradename '''Allelock''', manufactured by Kyowa Hakko Kogyo.<ref name=KYOWA08>{{cite web | author = Kyowa Hakko Kogyo Co., Ltd. | year = 2007 | url = http://www.e-search.ne.jp/~jpr/PDF/KYOWA08.PDF |format=PDF| title = ALLELOCK Tablets 2.5 & ALLELOCK Tablets 5 (English) | accessdate = 2008-08-10}}</ref>


It should not be used to treat irritation caused by [[contact lenses]]. The usual dose for Patanol is 1 drop in each affected eye 2 times per day, with 6 to 8 hours between doses. Both Pazeo and Pataday are dosed 1 drop in each eye daily.
It should not be used to treat irritation caused by [[contact lenses]]. The usual dose for Patanol is 1 drop in each affected eye 2 times per day, with 6 to 8 hours between doses. Both Pazeo and Pataday are dosed 1 drop in each eye daily.

Revision as of 19:00, 22 August 2017

Olopatadine
Clinical data
Trade namesPatanol and others
AHFS/Drugs.comMonograph
MedlinePlusa602025
Pregnancy
category
  • C
Routes of
administration		Ophthalmic, intranasal, oral
ATC code
Pharmacokinetic data
Elimination half-life3 hours
Identifiers
  • {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-
    dihydrodibenzo[b,e]oxepin-2-yl}acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H23NO3
Molar mass337.412 g/mol g·mol−1
3D model (JSmol)
  • O=C(O)Cc2ccc1OCc3c(C(\c1c2)=C\CCN(C)C)cccc3
  • InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- checkY
  • Key:JBIMVDZLSHOPLA-LSCVHKIXSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Olopatadine hydrochloride is an antihistamine (as well as anticholinergic and mast cell stabilizer), sold as a prescription eye drop manufactured by Alcon in one of three strengths: 0.7% solution or Pazeo in the US, 0.2% solution or Pataday (also called Patanol S in some countries), and 0.1% or Patanol (also called Opatanol in some countries; Olopat in India). It is used to treat itching associated with allergic conjunctivitis (eye allergies).[1] A steroid-free[2] nasal spray formulation is sold as Patanase, which was approved by the FDA on April 15, 2008.[3] It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by Kyowa Hakko Kogyo.[4]

It should not be used to treat irritation caused by contact lenses. The usual dose for Patanol is 1 drop in each affected eye 2 times per day, with 6 to 8 hours between doses. Both Pazeo and Pataday are dosed 1 drop in each eye daily.

There is potential for Olopatadine as a treatment modality for steroid rebound (red skin syndrome).[5]

Olopatadine was developed by Kyowa Hakko Kogyo.[6]

Side Effects

Some known side effects include headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, sore throat (pharyngitis), rhinitis, sinusitis, and taste perversion.

Synthesis

Olopatadine synthesis:[7]

See also

References

  1. ^ "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis". Cochrane Database Syst Rev. 6: CD009566. 2015. doi:10.1002/14651858.CD009566.pub2. PMID 26028608. {{cite journal}}: Cite uses deprecated parameter |authors= (help)
  2. ^ How PATANASE® Nasal Spray Works
  3. ^ Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
  4. ^ Kyowa Hakko Kogyo Co., Ltd. (2007). "ALLELOCK Tablets 2.5 & ALLELOCK Tablets 5 (English)" (PDF). Retrieved 2008-08-10.
  5. ^ Tamura T; Matsubara M; Hasegawa K; Ohmori K; Karasawa A. (2005). "Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity". Clin Exp Allergy. 35 (1): 97–103. doi:10.1111/j.1365-2222.2005.02147.x. PMID 15649273.
  6. ^ Kyowa Hakko Kogyo Co., Ltd. (2002). "Company History". Company Information. Kyowa Hakko Kogyo Co., Ltd. Retrieved 16 September 2010.
  7. ^ Ueno, K.; Kubo, S.; Tagawa, H.; Yoshioka, T.; Tsukada, W.; Tsubokawa, M.; Kojima, H.; Kasahara, A. (1976). "6,11-Dihydro-11-oxodibenz[b,e]oxepinacetic acids with potent antiinflammatory activity". Journal of Medicinal Chemistry. 19 (7): 941–946. doi:10.1021/jm00229a017.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Olopatadine&oldid=796733595"